46.69
price down icon1.41%   -0.67
after-market 시간 외 거래: 46.76 0.07 +0.15%
loading

Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스

pulisher
04:59 AM

Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative

04:59 AM
pulisher
08:55 AM

Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - Insider Monkey

08:55 AM
pulisher
07:17 AM

FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa

07:17 AM
pulisher
06:59 AM

FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan

06:59 AM
pulisher
Jul 20, 2025

Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Bristol Myers Squibb Company stock priceRapid wealth multiplication - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com

Jul 18, 2025
pulisher
Jul 18, 2025

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.

Jul 18, 2025
pulisher
Jul 18, 2025

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

Jul 18, 2025
pulisher
Jul 18, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 18, 2025
pulisher
Jul 18, 2025

13 Cheap Stocks Under $50 to Buy Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE

Jul 16, 2025
pulisher
Jul 16, 2025

Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters

Jul 16, 2025
pulisher
Jul 15, 2025

Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer in Schizophrenia Treatment - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Bristol-Myers Squibb’s New Alzheimer’s Study: A Potential Game Changer? - TipRanks

Jul 15, 2025
pulisher
Jul 14, 2025

Is Bristol-Myers Squibb Still an Undervalued Biopharma Play? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Benzinga

Jul 14, 2025
pulisher
Jul 14, 2025

Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Drug Development? - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research - ACCESS Newswire

Jul 14, 2025
pulisher
Jul 14, 2025

What To Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report - barchart.com

Jul 14, 2025
pulisher
Jul 13, 2025

Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income? - Insider Monkey

Jul 13, 2025
pulisher
Jul 12, 2025

Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating By Investing.com - Investing.com South Africa

Jul 12, 2025
pulisher
Jul 11, 2025

Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch

Jul 11, 2025
pulisher
Jul 11, 2025

Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

Bristol-Myers Squibb’s Melanoma Study Completion: Market Insights - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating - Investing.com India

Jul 11, 2025
pulisher
Jul 10, 2025

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce Pharma

Jul 10, 2025
pulisher
Jul 10, 2025

BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Bristol Myers Squibb: Hidden Vulnerabilities in the Blockbuster Model - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company - Seeking Alpha

Jul 10, 2025
pulisher
Jul 09, 2025

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Worldwide locations - Bristol Myers Squibb

Jul 09, 2025
pulisher
Jul 09, 2025

Bristol-Myers Squibb: Hold Rating Amid Revenue Growth and Strategic Challenges - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

Bristol-Myers Squibb Company (BMY) Announces New Clinical Trial for Breast Cancer Drug Iza-bren - Insider Monkey

Jul 09, 2025
pulisher
Jul 08, 2025

Ninth Circuit Confirms Bristol-Myers’ Rule Applies to Notice in FLSA Collective Actions - JD Supra

Jul 08, 2025
pulisher
Jul 08, 2025

Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading - Yahoo Finance

Jul 08, 2025
pulisher
Jul 03, 2025

Bristol-Myers Squibb’s New Study on Sickle Cell Disease: A Potential Market Game-Changer - TipRanks

Jul 03, 2025
drug_manufacturers_general SNY
$47.93
price down icon 0.81%
$108.28
price up icon 0.06%
drug_manufacturers_general PFE
$24.26
price down icon 0.86%
$295.87
price up icon 0.38%
drug_manufacturers_general MRK
$79.31
price down icon 0.81%
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
자본화:     |  볼륨(24시간):